Discover.
Launch.
Build.
Transform.
● Recent Highlights
Element Science
Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator. This milestone marks the beginning of a new era in protecting individuals at temporary risk of sudden cardiac arrest — with a device designed not just to save lives, but to do so without interrupting them.
Portfolio
Merida Biosciences
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today.
Merida Biosciences
Trace Neuroscience
Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases.
Trace Neuroscience
Candid Therapeutics
Candid Therapeutics is a biotechnology company dedicated to developing potentially transformative drugs to address autoimmune diseases.
Candid Therapeutics
Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company that is working to develop a new generation of medicines for cardiometabolic diseases.
Marea Therapeutics
Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry.
Seaport Therapeutics
bluebird bio
The FDA announced the approval of bluebird’s Lyfgenia for the treatment of sickle cell disease. Lyfgenia represents one of the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. SCD is a rare, debilitating and life-threatening blood disorder with significant unmet need. Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited.